A P3 Comparator Trial in Community Acquired Bacterial Pneumonia

Community Acquired Pneumonia Clinical Trial

Official title:

A Phase 3, Double-blinded, Randomized, Comparator Trial of the Safety and Efficacy of a Single Dose of Dalbavancin to Twice Daily Linezolid for the Treatment of Community Acquired Bacterial Pneumonia

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02269644
• Other study ID #: DUR001-305
• Secondary ID: 2014-002683-32
• Status: Withdrawn
• Phase: Phase 3
• First received: October 7, 2014
• Last updated: January 21, 2016
• Start date: November 2015
• Est. completion date: December 2016

Study information

• Verified date: January 2016
• Source: Durata Therapeutics Inc., an affiliate of Allergan plc
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study will be a double-blind, randomized, multicenter trial to assess the safety and efficacy of a single 1500 mg IV dose of dalbavancin plus a single 500 mg IV dose of azithromycin in comparison to an approved antibiotic regimen of linezolid 600 mg every 12 hours for 10-14 days plus a single 500 mg IV dose of azithromycin for the treatment of Community Acquired Bacterial Pneumonia.

Description:

This study will be a double-blind, randomized, multicenter trial to assess the safety and efficacy of a single 1500 mg IV dose of dalbavancin plus a single 500 mg IV dose of azithromycin in comparison to an approved antibiotic regimen of linezolid 600 mg every 12 hours for 10-14 days plus a single 500 mg IV dose of azithromycin for the treatment of CABP. Adult patients who meet all inclusion and none of the exclusion criteria will be randomized to one of the two treatment arms. Dosing will commence on Day 1, and all patients will receive a minimum of 10 days of therapy. Patients will be assessed on Day 1, Day 4-5, Day 7, Day 14 (End of Therapy, EOT), and Day 28 (Follow up).

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 2016
• Est. primary completion date: November 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Adults aged 18 to 85, inclusive

2. Has given written, informed consent

3. Has acute illness with onset within previous 7 days

4. Has at least 2 of the following symptoms:

• Difficulty breathing or shortness of breath

• Cough

• Production of purulent sputum

• Pleuritic chest pain

5. Has at least 2 vital sign abnormalities:

• Fever (> 38°C or < 35°C)

• Hypotension (systolic BP < 90 mm Hg)

• Tachycardia (> 100 beats /min)

• Tachypnea (> 24 breaths /min)

6. Has at least one other clinical or laboratory abnormalities:

• Hypoxemia (room air SaO2 < 90% )

• Clinical evidence of pulmonary consolidation

• Elevated WBC count or neutropenia (> 12,000/mm3 or < 4,000/mm3)

7. Has new lobar or multi-lobar infiltrates on chest radiograph

8. Has CURB-65 risk category 1 to 4. Patients with CURB-65 risk category 1 will be limited to 20% of the total patient population

Exclusion Criteria:

1. Contra-indication to the administration of any of the study treatments, such as hypersensitivity to any of the glycopeptide agents, beta-lactam agents, linezolid or macrolide antibiotics, or current or recent (within 2 weeks) use of MAO inhibitors or serotonergic antidepressants (within 5 weeks for fluoxetine) (see Section 5.5.1)

2. Has received antibiotic therapy in the 4 days prior to screening, with the following exception: up to 25% of patients may have received a single dose of a short acting (half life < 8 hours) antibiotic

3. Has aspiration pneumonia

4. Has hospital acquired or ventilator associated pneumonia, or healthcare associated pneumonia, or 2 or more days in hospital in the previous 90 days

5. Has cystic fibrosis or known or suspected Pneumocystis pneumonia or known or suspected active tuberculosis

6. Females of child-bearing potential who are unable to take adequate contraceptive precautions, have a positive pregnancy result within 24 hours prior to study entry, are known to be pregnant, or are currently breastfeeding an infant

7. Has primary or metastatic lung cancer

8. Has known bronchial obstruction or a history of post-obstructive pneumonia

9. Requires admission to ICU at baseline

10. Has empyema requiring drainage

11. Infection due to an organism known prior to study entry to be resistant to either treatment regimen

12. Has known or suspected infection due solely to an atypical pathogen such as Mycoplasma sp., Chlamydia sp. or Legionella sp. or positive Legionella urinary antigen at baseline

13. Absolute neutrophil count < 500 cells/mm3

14. Known or suspected human immunodeficiency virus (HIV) infected patients with a CD4 cell count < 200 cells/mm3 or with a past or current acquired immunodeficiency syndrome (AIDS)-defining condition and unknown CD4 count

15. Patients with a recent bone marrow transplant (in post-transplant hospital stay)

16. Patients receiving oral steroids > 40 mg prednisolone per day (or equivalent) or receiving immunosuppressant drugs after organ transplantation

17. Patients with a rapidly fatal illness, who are not expected to survive for 3 months

18. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study

19. Has participated in another trial of an investigational pharmaceutical product in the 30 days prior to enrollment

20. Prior participation in this trial.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Community Acquired Pneumonia
• Pneumonia
• Pneumonia, Bacterial

Intervention

Drug:
• Dalbavancin
dalbavancin 1500 mg IV over 30 minutes on Day 1
• Linezolid
linezolid 600 mg every 12 hours for a minimum of 10 days and a maximum of 14 days
• Linezolid Placebo
Dalbavancin randomized subjects after Day 1, 1st dose will receive linezolid placebo every 12 hours for a minimum of 10 days and a maximum of 14 days
• Azithromycin
Dalbavancin and linezolid randomized subjects on Day 1, 1st dose receive 500 mg of IV azithromycin

Locations

Country	Name	City	State
United States	Mercury Street Medical Group	Butte	Montana

Sponsors (1)

Lead Sponsor	Collaborator
Durata Therapeutics Inc., an affiliate of Allergan plc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment Response of CABP Symptoms	Compare the efficacy of a single 1500 mg dose of intravenous dalbavancin plus azithromycin to the comparator regimen (linezolid plus azithromycin). Response will be based on resolution of symptoms; including chest pain, shortness of breath (difficulty breathing), frequency/severity of cough and amount of sputum production. Each of these symptoms will be assessed on a 4 point scale (absent, mild, moderate or severe). A patient will be defined as a clinical responder if there is at least a 1 point improvement in 2 or more of these symptoms at 72-120 hours after randomization compared to baseline.	Change from Baseline to 72-120 hours after randomization	No
Secondary	Efficacy of dalbavancin to the comparator regimen	Test the efficacy of dalbavancin to the comparator regimen using alternative outcome measures including:1) improvement at Day 4-5 in at least two of the following symptoms with no worsening in any of these symptoms of CABP compared to baseline: chest pain, frequency or severity of cough, amount of productive sputum, and difficulty breathing and improvement in vital signs (i.e. temperature, heart rate, respiratory rate or blood pressure); 2) clinical outcome (using primary response criteria) at Day 14; 3) Investigator Assessment of Outcome at Day 14 and Day 28, with success defined as complete resolution of symptoms and signs attributable to CABP and did not receive non-trial antibacterial drugs for treatment of CABP.4) all-cause mortality at Day 28	Change from baseline to 72-120 hours after randomization, Day 14 and Day 28	No
Secondary	Safety Analysis	To test the safety profile of dalbavancin 1500 mg versus comparator. Safety will be assessed by means of physical examination and vital signs, collection of adverse, events and clinical laboratory tests through out the study.	Safety will be assessed at all time-points through Day 28	Yes